肝细胞癌的早期发现与治愈性治疗:法国和美国的成本效果分析
该研究从医疗系统角度,用马尔可夫模型比较肝硬化患者按指南监测(金标准监测)与真实世界监测的成本效果,转移概率主要来自法国CIRVIR和CHANGH两个队列,成本采用法国和美国收费标准,效果以生命年增益衡量,计算10年视野的增量成本效果比(ICER)。法国ICER为每生命年增益1754美元,美国为32415美元,健康增益来自更早诊断和获得一线治愈性治疗,其中射频消融(RFA)性价比最佳。结论认为金标准监测具有成本效果。
要点
- 法国金标准监测组成本87476美元 vs 真实世界监测组86829美元,ICER为每生命年增益1754美元。
- 美国金标准监测组成本93795美元 vs 真实世界监测组81829美元,ICER为每生命年增益32415美元。
- 生存增加0.37年(7.18 vs 6.81年),健康增益来自更早诊断和一线治愈性治疗,RFA性价比最佳。
核心结论
- 结果表明,对肝硬化患者进行金标准监测具有成本效果,归因于获得治愈性治疗的概率更高,从而生存概率更高。
研究设计与样本
- 经济评价采用马尔可夫模型,从医疗系统角度比较按指南推荐的肝硬化患者监测(金标准监测)与真实世界监测,模型描述疾病史和治疗过程包括当前一线治愈性治疗:肝切除、射频消融(RFA)和肝移植。
- 转移概率主要来自法国CIRVIR和CHANGH两个队列,成本采用法国和美国收费标准,效果以生命年增益(LYG)衡量,计算10年视野的增量成本效果比(ICER),并进行单因素和概率敏感性分析。
主要发现
- 法国金标准监测组成本87476美元 vs 真实世界监测组86829美元,成本差648美元。
- 美国金标准监测组成本93795美元 vs 真实世界监测组81829美元,成本差11965美元。
- 生存增加0.37年(7.18 vs 6.81年)。
- 法国ICER为每生命年增益1754美元,美国ICER为每生命年增益32415美元。
- 健康增益来自更早诊断和获得一线治愈性治疗,其中RFA性价比最佳。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
UNLABELLED: Hepatocellular carcinoma (HCC) is the leading cause of death in patients with cirrhosis. Patients outside clinical trials seldom benefit from evidence-based monitoring. The objective of this study was to estimate the cost-effectiveness of complying with HCC screening guidelines. The economic evaluation compared surveillance of patients with cirrhosis as recommended by the guidelines ("gold-standard monitoring") to "real-life monitoring" from the health care system perspective. A Markov model described the history of the disease and treatment course including current first-line curative treatment: liver resection, radiofrequency ablation (RFA), and liver transplantation. Transition probabilities were derived mainly from two French cohorts, CIRVIR and CHANGH. Costs were computed using French and U.S. tariffs. Effectiveness was measured in life years gained (LYG). An incremental cost-effectiveness ratio (ICER) was calculated for a 10-year horizon and tested with one-way and probabilistic sensitivity analyses. The cost difference between the two groups was $648 ($87,476 in the gold-standard monitoring group vs. $86,829 in the real-life monitoring group) in France and $11,965 ($93,795 vs. $81,829) in the United States. Survival increased by 0.37 years (7.18 vs. 6.81 years). The ICER was $1,754 per LYG in France and $32,415 per LYG in the United States. The health gain resulted from earlier diagnosis and access to first-line curative treatments, among which RFA provided the best value for money. CONCLUSION: Our results indicate that gold-standard monitoring for patients with cirrhosis is cost-effective, attributed to a higher probability of benefiting from a curative treatment and so a higher survival probability. (Hepatology 2017;65:1237-1248).
引用
- Cadier B, Bulsei J, Nahon P, et al. Early detection and curative treatment of hepatocellular carcinoma: A cost-effectiveness analysis in France and in the United States. Hepatology. 2017. PMID: 28176349. doi:10.1002/hep.28961
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。